138 related articles for article (PubMed ID: 33187861)
1. Transarterial Yttrium-90 Radioembolization of Hepatocellular Carcinoma Perfused by the Cystic Artery: Multi-institutional Feasibility Study.
Padia SA; Johnson GE; Lewandowski RJ; Gabr A; Toskich BB
J Vasc Interv Radiol; 2020 Dec; 31(12):2022-2027. PubMed ID: 33187861
[TBL] [Abstract][Full Text] [Related]
2. Radioembolization with infusion of yttrium-90 microspheres into a right inferior phrenic artery with hepatic tumor supply is feasible and safe.
Burgmans MC; Kao YH; Irani FG; Dames EL; Teo TK; Goh AS; Chow PK; Tay KH; Lo RH
J Vasc Interv Radiol; 2012 Oct; 23(10):1294-301. PubMed ID: 22922039
[TBL] [Abstract][Full Text] [Related]
3. Safety of Radioembolization via the Cystic Artery in Patients with Hepatocellular Carcinoma and Parasitized Arterial Supply.
Choi R; Lee M; Choi JW; Kim HC
J Vasc Interv Radiol; 2023 Oct; 34(10):1802-1808. PubMed ID: 37364731
[TBL] [Abstract][Full Text] [Related]
4. A simple method for estimating dose delivered to hepatocellular carcinoma after yttrium-90 glass-based radioembolization therapy: preliminary results of a proof of concept study.
Kokabi N; Galt JR; Xing M; Camacho JC; Barron BJ; Schuster DM; Kim HS
J Vasc Interv Radiol; 2014 Feb; 25(2):277-87. PubMed ID: 24461133
[TBL] [Abstract][Full Text] [Related]
5. Prophylactic embolization of the cystic artery before radioembolization: feasibility, safety, and outcomes.
McWilliams JP; Kee ST; Loh CT; Lee EW; Liu DM
Cardiovasc Intervent Radiol; 2011 Aug; 34(4):786-92. PubMed ID: 21063871
[TBL] [Abstract][Full Text] [Related]
6. Same-Day Yttrium-90 Radioembolization: Feasibility with Resin Microspheres.
Li MD; Chu KF; DePietro A; Wu V; Wehrenberg-Klee E; Zurkiya O; Liu RW; Ganguli S
J Vasc Interv Radiol; 2019 Mar; 30(3):314-319. PubMed ID: 30819470
[TBL] [Abstract][Full Text] [Related]
7. Feasibility of Boosted Radioembolization for Hepatocellular Carcinoma Larger than 5 cm.
Kim HC; Kim YJ; Lee JH; Suh KS; Chung JW
J Vasc Interv Radiol; 2019 Jan; 30(1):1-8. PubMed ID: 30293734
[TBL] [Abstract][Full Text] [Related]
8. Transarterial radioembolization versus chemoembolization for the treatment of hepatocellular carcinoma (TRACE): study protocol for a randomized controlled trial.
Seinstra BA; Defreyne L; Lambert B; Lam MG; Verkooijen HM; van Erpecum KJ; van Hoek B; van Erkel AR; Coenraad MJ; Al Younis I; van Vlierberghe H; van den Bosch MA
Trials; 2012 Aug; 13():144. PubMed ID: 22913492
[TBL] [Abstract][Full Text] [Related]
9. Yttrium-90 Radioembolization as a Salvage Treatment following Chemoembolization for Hepatocellular Carcinoma.
Johnson GE; Monsky WL; Valji K; Hippe DS; Padia SA
J Vasc Interv Radiol; 2016 Aug; 27(8):1123-9. PubMed ID: 27321889
[TBL] [Abstract][Full Text] [Related]
10. Microsphere localization and dose quantification using positron emission tomography/CT following hepatic intraarterial radioembolization with yttrium-90 in patients with advanced hepatocellular carcinoma.
Lea WB; Tapp KN; Tann M; Hutchins GD; Fletcher JW; Johnson MS
J Vasc Interv Radiol; 2014 Oct; 25(10):1595-603. PubMed ID: 25156647
[TBL] [Abstract][Full Text] [Related]
11. Safety of Radioembolization in the Setting of Angiographically Apparent Arterioportal Shunting.
Thornton LM; Geller BS; Pepin EW; Shah JL; Kapp M; Toskich BB
J Vasc Interv Radiol; 2018 Nov; 29(11):1511-1518. PubMed ID: 30293727
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma.
Golfieri R; Bilbao JI; Carpanese L; Cianni R; Gasparini D; Ezziddin S; Paprottka PM; Fiore F; Cappelli A; Rodriguez M; Ettorre GM; Saltarelli A; Geatti O; Ahmadzadehfar H; Haug AR; Izzo F; Giampalma E; Sangro B; Pizzi G; Notarianni E; Vit A; Wilhelm K; Jakobs TF; Lastoria S;
J Hepatol; 2013 Oct; 59(4):753-61. PubMed ID: 23707371
[TBL] [Abstract][Full Text] [Related]
13. Tumor Targeting and Three-Dimensional Voxel-Based Dosimetry to Predict Tumor Response, Toxicity, and Survival after Yttrium-90 Resin Microsphere Radioembolization in Hepatocellular Carcinoma.
Allimant C; Kafrouni M; Delicque J; Ilonca D; Cassinotto C; Assenat E; Ursic-Bedoya J; Pageaux GP; Mariano-Goulart D; Aho S; Guiu B
J Vasc Interv Radiol; 2018 Dec; 29(12):1662-1670.e4. PubMed ID: 30217745
[TBL] [Abstract][Full Text] [Related]
14. Radioembolization with Yttrium-90 Microspheres for the Treatment of Liver Metastases of Pancreatic Adenocarcinoma: A Multicenter Analysis.
Kim AY; Frantz S; Brower J; Akhter N
J Vasc Interv Radiol; 2019 Mar; 30(3):298-304.e2. PubMed ID: 30819469
[TBL] [Abstract][Full Text] [Related]
15. Safety of Combined Yttrium-90 Radioembolization and Immune Checkpoint Inhibitor Immunotherapy for Hepatocellular Carcinoma.
Zhan C; Ruohoniemi D; Shanbhogue KP; Wei J; Welling TH; Gu P; Park JS; Dagher NN; Taslakian B; Hickey RM
J Vasc Interv Radiol; 2020 Jan; 31(1):25-34. PubMed ID: 31422022
[TBL] [Abstract][Full Text] [Related]
16. Ablative Transarterial Radioembolization of a Parasitized Adrenal Artery for the Treatment of Hepatocellular Carcinoma.
Vidal LLC; Frey GT; Ritchie C; Lewis A; Paz-Fumagalli R; McKinney M; Toskich BB
J Vasc Interv Radiol; 2019 Mar; 30(3):473-476. PubMed ID: 30819498
[No Abstract] [Full Text] [Related]
17. Superselective yttrium-90 radioembolization for hepatocellular carcinoma yields high response rates with minimal toxicity.
Padia SA; Kwan SW; Roudsari B; Monsky WL; Coveler A; Harris WP
J Vasc Interv Radiol; 2014 Jul; 25(7):1067-73. PubMed ID: 24837982
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of Yttrium-90 Radioembolization for Unresectable Combined Biphenotypic Hepatocellular-Cholangiocarcinoma.
Malone CD; Gibby W; Tsai R; Kim SK; Lancia S; Akinwande O; Ramaswamy RS
J Vasc Interv Radiol; 2020 May; 31(5):701-709. PubMed ID: 32127318
[TBL] [Abstract][Full Text] [Related]
19. Toxicity and Survival of Hepatocellular Carcinoma Patients with Hepatitis B Infection Treated with Yttrium-90 Radioembolization: An Updated 15-Year Study.
Gao R; Gabr A; Mouli S; Riaz A; Kulik L; Lewandowski RJ; Salem R
J Vasc Interv Radiol; 2020 Mar; 31(3):401-408.e1. PubMed ID: 31983593
[TBL] [Abstract][Full Text] [Related]
20. Image-guided personalized predictive dosimetry by artery-specific SPECT/CT partition modeling for safe and effective 90Y radioembolization.
Kao YH; Hock Tan AE; Burgmans MC; Irani FG; Khoo LS; Gong Lo RH; Tay KH; Tan BS; Hoe Chow PK; Eng Ng DC; Whatt Goh AS
J Nucl Med; 2012 Apr; 53(4):559-66. PubMed ID: 22343503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
